Ocular Therapeutix, Inc.

NasdaqGM:OCUL 주식 보고서

시가총액: US$1.6b

Ocular Therapeutix 미래 성장

Future 기준 확인 2/6

Ocular Therapeutix은 연간 수입과 매출이 각각 23.9%와 38.9% 증가할 것으로 예상되고 EPS는 연간 26.4%만큼 증가할 것으로 예상됩니다.

주요 정보

23.9%

수익 성장률

26.4%

EPS 성장률

Pharmaceuticals 수익 성장23.6%
매출 성장률38.9%
향후 자기자본 수익률n/a
애널리스트 커버리지

Good

마지막 업데이트29 Oct 2024

최근 미래 성장 업데이트

Earnings Update: Ocular Therapeutix, Inc. (NASDAQ:OCUL) Just Reported Its Second-Quarter Results And Analysts Are Updating Their Forecasts

Aug 10
Earnings Update: Ocular Therapeutix, Inc. (NASDAQ:OCUL) Just Reported Its Second-Quarter Results And Analysts Are Updating Their Forecasts

Recent updates

Is Ocular Therapeutix (NASDAQ:OCUL) Weighed On By Its Debt Load?

Oct 16
Is Ocular Therapeutix (NASDAQ:OCUL) Weighed On By Its Debt Load?

Ocular Therapeutix: Focus On Axpaxli's Path To Market In Wet-AMD And Implications To Investors

Oct 11

Earnings Update: Ocular Therapeutix, Inc. (NASDAQ:OCUL) Just Reported Its Second-Quarter Results And Analysts Are Updating Their Forecasts

Aug 10
Earnings Update: Ocular Therapeutix, Inc. (NASDAQ:OCUL) Just Reported Its Second-Quarter Results And Analysts Are Updating Their Forecasts

Ocular Therapeutix: A Speculative Investment For Risk-Tolerant Investors

Jul 23

Ocular Therapeutix, Inc. (NASDAQ:OCUL) Stocks Shoot Up 41% But Its P/S Still Looks Reasonable

Jul 15
Ocular Therapeutix, Inc. (NASDAQ:OCUL) Stocks Shoot Up 41% But Its P/S Still Looks Reasonable

Ocular Therapeutix, Inc. (NASDAQ:OCUL) Shares Could Be 45% Below Their Intrinsic Value Estimate

Jun 05
Ocular Therapeutix, Inc. (NASDAQ:OCUL) Shares Could Be 45% Below Their Intrinsic Value Estimate

Ocular Therapeutix: Unveiling Pipeline Progress (AXPAXLI, PAXTRAVA) And Q1 Results

Jun 01

Ocular Therapeutics' Impressive Surge: A Strategic Insight

Mar 19

Ocular Therapeutix: Diabetic Retinopathy Data Q2 2024 And Wet AMD Advancement

Feb 11

Ocular Therapeutix Vies With Gene Therapies, Not Just Eylea, For Wet AMD

Jan 10

Optimistic Investors Push Ocular Therapeutix, Inc. (NASDAQ:OCUL) Shares Up 31% But Growth Is Lacking

Jan 09
Optimistic Investors Push Ocular Therapeutix, Inc. (NASDAQ:OCUL) Shares Up 31% But Growth Is Lacking

Is Ocular Therapeutix (NASDAQ:OCUL) Using Too Much Debt?

Oct 15
Is Ocular Therapeutix (NASDAQ:OCUL) Using Too Much Debt?

Is Ocular Therapeutix (NASDAQ:OCUL) Weighed On By Its Debt Load?

Jun 30
Is Ocular Therapeutix (NASDAQ:OCUL) Weighed On By Its Debt Load?

Analysts Just Slashed Their Ocular Therapeutix, Inc. (NASDAQ:OCUL) EPS Numbers

Mar 08
Analysts Just Slashed Their Ocular Therapeutix, Inc. (NASDAQ:OCUL) EPS Numbers

Is Ocular Therapeutix (NASDAQ:OCUL) Using Debt In A Risky Way?

Feb 11
Is Ocular Therapeutix (NASDAQ:OCUL) Using Debt In A Risky Way?

Ocular Therapeutix, Inc. (NASDAQ:OCUL) Analysts Are More Bearish Than They Used To Be

Nov 16
Ocular Therapeutix, Inc. (NASDAQ:OCUL) Analysts Are More Bearish Than They Used To Be

Despite Lacking Profits Ocular Therapeutix (NASDAQ:OCUL) Seems To Be On Top Of Its Debt

Sep 09
Despite Lacking Profits Ocular Therapeutix (NASDAQ:OCUL) Seems To Be On Top Of Its Debt

Ocular Therapeutix: Trading Ahead Of An Underappreciated Catalyst Event

Aug 15

수익 및 매출 성장 예측

NasdaqGM:OCUL - 애널리스트의 미래 추정치 및 과거 재무 데이터 (USD Millions )
날짜수익수익잉여 현금 흐름작전 현금평균 애널리스트 수
12/31/202695-159-95-1487
12/31/202575-164-138-1359
12/31/202466-182-144-1759
6/30/202461-138-91-89N/A
3/31/202460-115-87-84N/A
12/31/202358-81-76-70N/A
9/30/202358-67-73-65N/A
6/30/202355-91-78-70N/A
3/31/202352-89-68-61N/A
12/31/202251-71-63-60N/A
9/30/202250-59-60-58N/A
6/30/202250-33-59-58N/A
3/31/202249-22-68-67N/A
12/31/202144-7-67-66N/A
9/30/202139-88-57-57N/A
6/30/202132-103-58-57N/A
3/31/202122-131-53-52N/A
12/31/202017-156-54-54N/A
9/30/202012-96-68-67N/A
6/30/20207-103-74-73N/A
3/31/20206-91-79-77N/A
12/31/20194-86-80-78N/A
9/30/20192-78-74-72N/A
6/30/20192-74-65-63N/A
3/31/20192-63-58-56N/A
12/31/20182-60-51-49N/A
9/30/20182-56-48-46N/A
6/30/20182-56-53-49N/A
3/31/20182-61N/A-48N/A
12/31/20172-63N/A-50N/A
9/30/20172-63N/A-48N/A
6/30/20172-57N/A-41N/A
3/31/20172-50N/A-39N/A
12/31/20162-45N/A-34N/A
9/30/20162-43N/A-35N/A
6/30/20162-44N/A-37N/A
3/31/20162-43N/A-36N/A
12/31/20152-40N/A-34N/A
9/30/20152-37N/A-31N/A
6/30/20152-33N/A-27N/A
3/31/20151-29N/A-23N/A
12/31/20141-29N/A-20N/A
9/30/20140-24N/A-18N/A
6/30/20140-20N/A-15N/A
3/31/20140-17N/A-13N/A

애널리스트 미래 성장 예측

수입 대 저축률: OCUL 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

수익 vs 시장: OCUL 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

고성장 수익: OCUL 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

수익 대 시장: OCUL 의 수익(연간 38.9% ) US 시장( 8.8% 보다 빠르게 성장할 것으로 예상됩니다. 8.8% 연간).

고성장 수익: OCUL 의 수익(연간 38.9% )은 연간 20% 보다 빠르게 증가할 것으로 예상됩니다.


주당 순이익 성장 예측


미래 자기자본 수익률

미래 ROE: OCUL 의 자기자본수익률이 3년 내에 높을 것으로 예상되는지 판단하기에는 데이터가 부족합니다.


성장 기업 발견